In 2023, semaglutide — the active ingredient in Ozempic and Wegovy — was named Science magazine's Breakthrough of the Year. Not a new antibiotic. Not a cancer therapy. A weight loss drug. That distinction tells you something about how profoundly these medications have shifted the medical landscape.

GLP-1 receptor agonists have generated more public attention than perhaps any drug class since statins. Celebrities post about them on social media. Pharmacies report nationwide shortages. The market cap of Novo Nordisk, the company behind semaglutide, briefly surpassed the entire GDP of Denmark. Meanwhile, patients with type 2 diabetes who have relied on these drugs for years struggle to fill their prescriptions.

But beneath the hype, there is serious science. Randomized controlled trials involving tens of thousands of participants. Cardiovascular outcome data. Long-term safety follow-up. And important questions that the headlines rarely address: What happens to your body when you stop taking these drugs? Who actually benefits most? What are the real risks?

This article cuts through the noise. We will walk through how GLP-1 drugs work at a molecular level, what the landmark clinical trials actually found, the side effects clinicians are watching most carefully, the weight regain problem, the cost and access crisis, and what role lifestyle changes play alongside medication.

How GLP-1 Drugs Work: The Incretin System

To understand these medications, you need to understand a hormone system that most people have never heard of: the incretin system.

When you eat food, specialized cells in your small intestine release a hormone called glucagon-like peptide-1 (GLP-1). This hormone does several things simultaneously. It signals the pancreas to release insulin, which lowers blood sugar. It tells the pancreas to stop releasing glucagon, a hormone that raises blood sugar. It slows the rate at which food empties from your stomach. And — critically for weight management — it acts on receptors in the brain's hypothalamus and brainstem to reduce appetite.

In healthy people, natural GLP-1 is released after meals and degraded within minutes by an enzyme called dipeptidyl peptidase-4 (DPP-4). The signal is brief and proportional to the meal.

GLP-1 receptor agonist drugs are synthetic versions of this hormone, engineered to resist degradation. Semaglutide, for example, has a half-life of approximately 7 days — compared to roughly 2 minutes for natural GLP-1. This means a once-weekly injection provides continuous receptor activation, producing sustained appetite suppression that natural GLP-1 never achieves.

The appetite effects are profound. Brain imaging studies using functional MRI have shown that semaglutide reduces activity in brain regions associated with food reward and craving. Patients consistently report not just eating less, but genuinely wanting less food. Many describe a quieting of the persistent mental chatter about food — what researchers call reduced "food noise."

Tirzepatide (sold as Mounjaro and Zepbound) takes this a step further. It is a dual agonist, activating both GLP-1 receptors and glucose-dependent insulinotropic polypeptide (GIP) receptors. GIP is another incretin hormone, and combining both pathways appears to produce even greater effects on appetite, blood sugar regulation, and weight loss than GLP-1 alone.

The Drug Landscape: Semaglutide vs. Tirzepatide

The GLP-1 drug category has expanded rapidly. Here are the key medications and their approved uses as of early 2026:

Semaglutide (Novo Nordisk)

  • Ozempic — FDA-approved for type 2 diabetes (0.5 mg, 1 mg, 2 mg doses)
  • Wegovy — FDA-approved for chronic weight management (2.4 mg dose)
  • Rybelsus — oral semaglutide tablet, approved for type 2 diabetes

Tirzepatide (Eli Lilly)

  • Mounjaro — FDA-approved for type 2 diabetes (5 mg to 15 mg doses)
  • Zepbound — FDA-approved for chronic weight management (same molecule, weight-specific branding)

Liraglutide (Novo Nordisk)

  • Victoza — for type 2 diabetes
  • Saxenda — for weight management (the predecessor to Wegovy, with less dramatic results)

The distinction between the diabetes-branded and weight-branded versions matters primarily for insurance coverage and dosing. Ozempic and Mounjaro are the same molecules as Wegovy and Zepbound, respectively — just approved under different names for different indications, often at different doses.

Semaglutide and tirzepatide are both administered as once-weekly subcutaneous injections using a prefilled pen. Patients titrate up from a starting dose over several weeks to minimize gastrointestinal side effects. The full therapeutic dose for weight management is typically semaglutide 2.4 mg or tirzepatide 10–15 mg weekly.

The STEP Trials: Semaglutide's Evidence Base

The clinical evidence for semaglutide in weight management comes primarily from the STEP (Semaglutide Treatment Effect in People with Obesity) trial program — a series of large, randomized, double-blind, placebo-controlled trials.

STEP 1 enrolled 1,961 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, but without diabetes. After 68 weeks of semaglutide 2.4 mg weekly plus lifestyle intervention, participants lost a mean of 14.9% of their body weight, compared to 2.4% with placebo. One-third of participants lost more than 20% of their body weight. Published in the New England Journal of Medicine in 2021, these results were unprecedented for a pharmacological intervention.

STEP 2 studied semaglutide specifically in people with type 2 diabetes and obesity. Mean weight loss was 9.6% with semaglutide 2.4 mg versus 3.4% with placebo — lower than STEP 1, which is expected because weight loss is generally harder to achieve in patients with type 2 diabetes.

STEP 3 combined semaglutide with intensive behavioral therapy (30 counseling sessions over 68 weeks). The result: 16.0% mean weight loss, suggesting that combining medication with structured lifestyle support produces the best outcomes.

STEP 5 extended the observation period to 104 weeks (2 years). Mean weight loss was 15.2% at the end of treatment, and — critically — the weight loss was sustained for the full duration of continued drug use. This addressed a key question: does the effect wear off? The data says no, as long as you keep taking the medication.

Across the STEP program, semaglutide consistently produced weight loss in the range of 15–17% of body weight in non-diabetic populations — roughly three to four times the effect seen with older weight loss drugs.

SURMOUNT Trials: Tirzepatide Raises the Bar

If the STEP results were impressive, the SURMOUNT trials for tirzepatide were remarkable.

SURMOUNT-1 enrolled 2,539 adults with obesity or overweight (without diabetes). At 72 weeks, mean weight loss was 15.0% with tirzepatide 5 mg, 19.5% with 10 mg, and 20.9% with 15 mg — compared to 3.1% with placebo. More than one-third of participants on the highest dose lost over 25% of their body weight. Published in the New England Journal of Medicine in 2022, these results approached what was previously only achievable with bariatric surgery.

SURMOUNT-2 focused on participants with type 2 diabetes, where tirzepatide 15 mg produced 14.7% weight loss versus 3.2% with placebo.

SURMOUNT-3 combined tirzepatide with an intensive 12-week lifestyle lead-in period. Participants first lost 6.9% of body weight through diet and exercise alone, then were randomized to tirzepatide or placebo. Those on tirzepatide lost an additional 18.4% from randomization, for a total loss of approximately 26% from their original weight.

The head-to-head comparison tells a clear story: tirzepatide's dual GIP/GLP-1 mechanism appears to produce approximately 5 percentage points more weight loss than semaglutide alone. Whether this translates to better long-term health outcomes remains an active area of investigation.

Beyond Weight: Cardiovascular Benefits

The most consequential recent development in GLP-1 research may not be about weight at all. It is about the heart.

The SELECT trial, published in the New England Journal of Medicine in 2023, enrolled 17,604 adults aged 45 and older with established cardiovascular disease, a BMI of 27 or higher, and no diabetes. Participants were randomized to semaglutide 2.4 mg weekly or placebo and followed for a mean of 39.8 months.

The primary endpoint — a composite of cardiovascular death, nonfatal heart attack, or nonfatal stroke — occurred in 6.5% of the semaglutide group versus 8.0% of the placebo group. That translates to a 20% relative risk reduction. Semaglutide reduced the risk of heart attacks, strokes, and cardiovascular death in people who already had heart disease.

This was a landmark finding. For the first time, a weight management drug demonstrated cardiovascular benefit in a rigorous outcomes trial. Previous weight loss drugs had either shown no cardiovascular benefit or, in some cases, had been pulled from the market over cardiovascular safety concerns (fenfluramine, sibutramine).

Based on the SELECT data, the FDA expanded Wegovy's label to include cardiovascular risk reduction — making semaglutide the first weight management drug to carry such an indication. This has major implications for insurance coverage and clinical practice, because it reframes these medications not just as weight loss tools but as cardiovascular risk reducers.

Researchers are also investigating GLP-1 agonists for heart failure with preserved ejection fraction (HFpEF), chronic kidney disease, metabolic-associated steatotic liver disease (MASLD, formerly NAFLD), and obstructive sleep apnea. Early results from the STEP-HFpEF trial showed significant improvements in heart failure symptoms and physical limitations with semaglutide.

Side Effects: What the Data Shows

GLP-1 receptor agonists are not side-effect-free, and understanding the risk profile is essential for informed decision-making.

Gastrointestinal effects are by far the most common. Across the STEP and SURMOUNT trials, nausea affected 40–50% of participants on active drug (versus ~15% on placebo), vomiting affected 20–30%, diarrhea 25–35%, and constipation 20–25%. These effects are typically worst during dose escalation and improve over weeks to months. However, roughly 5–7% of trial participants discontinued treatment due to GI side effects.

The slow titration schedule exists specifically to mitigate these effects. Rushing to the full dose — which sometimes happens when patients obtain medication outside of supervised medical care — significantly increases the risk of severe nausea and vomiting.

Muscle loss is a legitimate concern. Weight loss from any intervention — diet, surgery, or medication — involves losing both fat and lean mass. In the STEP 1 trial, body composition analysis showed that approximately 40% of weight lost was lean mass, including muscle. This ratio is roughly similar to what occurs with diet-induced weight loss, but the magnitude of total weight loss with GLP-1 drugs means the absolute amount of muscle lost can be significant.

Resistance training during GLP-1 therapy is strongly recommended by endocrinologists and obesity medicine specialists to preserve muscle mass. Adequate protein intake — generally 1.2 to 1.6 grams per kilogram of body weight daily — is equally important. Tracking your food intake and ensuring adequate protein is one of the most actionable steps you can take while on these medications. WatchMyHealth's food logging feature lets you monitor daily protein specifically, which becomes especially relevant during pharmacological weight loss.

"Ozempic face" is the colloquial term for the facial volume loss that can accompany significant weight loss — hollowed cheeks, sagging skin, a more aged appearance. This is not unique to GLP-1 drugs; it occurs with any rapid, substantial weight loss. The face has relatively little subcutaneous fat, so even moderate fat loss can be visually noticeable. Dermatologists note that the effect is more pronounced in older patients and those who lose weight very quickly.

Pancreatitis has been a theoretical concern since the early days of GLP-1 agonists. Large meta-analyses, including data from cardiovascular outcome trials, have not confirmed a statistically significant increased risk of pancreatitis with semaglutide or tirzepatide. However, these medications are contraindicated in patients with a history of pancreatitis, and clinicians monitor for symptoms.

Thyroid concerns: In rodent studies, GLP-1 agonists caused thyroid C-cell tumors (medullary thyroid carcinoma). This has not been observed in human trials or post-marketing surveillance. Nevertheless, GLP-1 drugs carry a boxed warning and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Gallbladder disease: Rapid weight loss increases the risk of gallstones, and this applies to GLP-1-mediated weight loss as well. The STEP trials reported higher rates of cholelithiasis (gallstones) and cholecystitis in the semaglutide groups compared to placebo.

The Weight Regain Problem

Perhaps the most important finding in GLP-1 research — and the one least discussed in popular media — concerns what happens when patients stop the medication.

The STEP 1 extension trial followed participants for an additional year after they stopped semaglutide at week 68. By week 120, participants had regained two-thirds of the weight they had lost. They also lost the improvements in cardiometabolic risk factors — waist circumference, blood pressure, lipid levels, and HbA1c — that they had achieved during treatment.

This finding was published in Diabetes, Obesity and Metabolism in 2022 and fundamentally reshaped the clinical conversation around these drugs. Obesity, the data suggests, behaves like a chronic disease — more like hypertension or type 2 diabetes than like an acute infection. Just as blood pressure rises when you stop antihypertensives, weight returns when you stop GLP-1 agonists.

The biological explanation involves multiple compensatory mechanisms. When you lose weight, levels of leptin (the satiety hormone) drop, ghrelin (the hunger hormone) rises, and your resting metabolic rate decreases. These changes persist for years after weight loss and create a powerful physiological drive to regain. GLP-1 drugs override these signals while you take them. When you stop, the signals reassert themselves.

This has profound implications for treatment planning. Many patients and clinicians initially approached GLP-1 drugs as a temporary intervention — lose the weight, stop the drug, maintain the loss through lifestyle changes. The data suggests this works for only a minority of patients. Most will require indefinite treatment to maintain their weight loss, which raises serious questions about long-term cost, supply, and sustainability.

Tracking your weight consistently during and after any medication change provides the objective data you need to make informed decisions with your doctor. WatchMyHealth's weight tracking shows your trend over months and years — the kind of long-term view that is essential when managing a chronic condition.

Who Qualifies for GLP-1 Therapy?

GLP-1 receptor agonists for weight management are not indicated for cosmetic weight loss or for people who want to lose a few vanity pounds. The FDA-approved indications are specific:

Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are approved for chronic weight management in adults with:

  • BMI ≥30 (obesity), OR
  • BMI ≥27 (overweight) with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease)

Wegovy additionally carries the cardiovascular indication for adults with established cardiovascular disease and BMI ≥27, regardless of diabetes status.

In clinical practice, prescribers typically also assess:

  • History of prior weight loss attempts through diet and exercise
  • Presence of metabolic syndrome
  • Impact of excess weight on quality of life and functional status
  • Contraindications (personal/family history of medullary thyroid carcinoma, MEN2, pancreatitis, pregnancy)
  • Mental health considerations (history of eating disorders, suicidal ideation — post-marketing reports have prompted ongoing investigation)

The American Gastroenterological Association's 2022 clinical practice guideline recommends pharmacotherapy as an adjunct to lifestyle modification for patients with BMI ≥30 or BMI ≥27 with weight-related complications, noting that medications should be continued long-term if effective and well-tolerated.

For children and adolescents, Wegovy is approved for patients aged 12 and older with obesity. The STEP TEENS trial showed 16.1% mean weight loss in adolescents, similar to the adult trials.

The Cost and Access Crisis

The clinical promise of GLP-1 drugs runs headlong into a practical reality: they are extraordinarily expensive.

The list price for Wegovy in the United States is approximately $1,350 per month. Zepbound lists at roughly $1,060 per month. Without insurance coverage, annual costs exceed $12,000–$16,000 — and since the evidence suggests most patients need indefinite treatment, the lifetime cost for an individual could reach six figures.

Insurance coverage is inconsistent and often restrictive. Medicare Part D was, until recently, prohibited from covering anti-obesity medications. The Inflation Reduction Act of 2022 did not change this. Some private insurers cover GLP-1 drugs for weight management, but many impose strict prior authorization requirements, step therapy (requiring failure of older, cheaper drugs first), BMI thresholds, or outright exclusions.

Employer-sponsored health plans are increasingly adding coverage as the cardiovascular data strengthens the cost-effectiveness argument. A cost-effectiveness analysis published in JAMA Internal Medicine estimated that semaglutide for weight management would meet standard willingness-to-pay thresholds at a price roughly 40–60% below the current list price — meaning the drugs are clinically effective but arguably overpriced relative to the health system's capacity to pay.

The supply situation has also been strained. From 2022 through early 2025, both Ozempic and Wegovy experienced recurring shortages as demand surged beyond manufacturing capacity. Novo Nordisk invested billions in expanding production, and supply has improved, but periodic disruptions continue in some markets.

The Compounding Pharmacy Controversy

The drug shortages created a parallel market: compounding pharmacies producing versions of semaglutide and tirzepatide at a fraction of the branded price.

Under FDA regulations, compounding pharmacies can produce copies of drugs that are on the FDA's shortage list. While semaglutide and tirzepatide were listed as being in shortage, compounding pharmacies legally produced and sold them — often for $200–$500 per month, dramatically less than the branded versions.

However, compounded drugs are not FDA-approved. They are not subject to the same manufacturing standards, purity testing, or bioequivalence requirements as branded pharmaceuticals. The FDA and the drug manufacturers have repeatedly warned about quality control concerns, including reports of compounded semaglutide products containing incorrect doses, impurities, or salt forms (semaglutide sodium versus semaglutide base) that may not be bioequivalent.

In late 2024 and into 2025, as supply of branded products improved, the FDA removed semaglutide from the shortage list. This triggered legal battles, as compounding pharmacies argued that patient access would be devastated by forcing everyone back to the high-priced branded versions. Novo Nordisk and Eli Lilly pursued legal action against compounders. The situation remains legally and ethically complex.

For patients, the practical concern is straightforward: compounded products are cheaper but carry unknown quality risks. Patients using compounded GLP-1 drugs should be under medical supervision and should monitor their response carefully — including tracking weight trends, blood sugar if diabetic, and any side effects. If you are using any form of these medications, logging them in a medication tracker along with your weight data gives both you and your physician objective information about whether the treatment is working as expected.

Lifestyle Changes Alongside Medication

GLP-1 drugs are explicitly approved as an adjunct to lifestyle modification — not as a replacement for it. Every major trial combined the drug with dietary counseling and physical activity recommendations. The question is not whether lifestyle matters, but how to optimize it during pharmacotherapy.

Protein intake becomes especially important. As discussed in the side effects section, significant lean mass loss accompanies weight loss on GLP-1 drugs. A 2024 position statement from the Obesity Medicine Association recommends 1.2–1.6 g/kg/day of protein for patients on anti-obesity medications, with higher targets for older adults or those engaged in resistance training. Since GLP-1 drugs suppress appetite, patients often need to deliberately plan protein-rich meals rather than relying on hunger cues.

Resistance training is the primary intervention for preserving muscle during weight loss. A meta-analysis published in Obesity Reviews found that combining resistance exercise with caloric restriction preserved significantly more lean mass than caloric restriction alone. While no large randomized trial has specifically studied resistance training plus GLP-1 therapy, the physiological rationale is strong and the recommendation is near-universal among obesity medicine specialists.

Cardiovascular exercise remains important for metabolic health, cardiovascular fitness, and mental well-being — independent of its modest effect on weight loss.

Behavioral strategies — meal planning, mindful eating, sleep optimization, stress management — do not become irrelevant just because a drug is suppressing appetite. These habits contribute to long-term weight maintenance and metabolic health. Patients who build strong behavioral foundations while on medication may fare better if they eventually discontinue or reduce their dose.

The combination of medication and robust lifestyle intervention appears to produce the best outcomes. STEP 3, which paired semaglutide with intensive behavioral therapy, produced the highest weight loss in the semaglutide trial program. This suggests a synergistic effect: the drug makes it easier to implement lifestyle changes, and the lifestyle changes amplify the drug's effects.

What the Future Holds

The GLP-1 field is evolving rapidly, with several developments on the horizon.

Oral semaglutide for weight management is in late-stage trials. Novo Nordisk's OASIS 1 trial showed that oral semaglutide 50 mg daily produced 15.1% weight loss at 68 weeks — comparable to injectable semaglutide. If approved, an effective pill could dramatically improve access and patient adherence.

Next-generation multi-agonists are in development. Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, produced up to 24.2% weight loss in a phase 2 trial at 48 weeks. CagriSema combines semaglutide with cagrilintide (an amylin analog) and has shown promising early results exceeding semaglutide alone.

Muscle-sparing approaches are being investigated, including combination of GLP-1 drugs with myostatin inhibitors or other agents that promote lean mass preservation. The muscle loss problem is taken seriously, and addressing it pharmacologically could remove one of the key concerns about rapid weight loss.

Longer-duration formulations — potentially monthly injections — are in development and could improve convenience and adherence.

Biosimilars for semaglutide are expected to enter the market as patents expire, potentially driving costs down significantly. Several companies have announced biosimilar development programs.

Making Informed Decisions

GLP-1 receptor agonists represent a genuine advance in obesity treatment. The clinical trial data is robust. The cardiovascular benefits are real. For patients who meet the criteria and can access these medications, they offer a tool that was simply not available five years ago.

But they are not magic. They come with side effects, they require indefinite use for most patients, they are expensive, and they work best when combined with the lifestyle fundamentals that matter regardless of medication status: adequate protein, regular exercise, sleep, stress management, and consistent self-monitoring.

If you are considering these medications, or are already taking them, a few principles are worth keeping in mind:

  • Track your weight trend, not individual readings. GLP-1 drugs produce steady weight loss over months. Weekly fluctuations mean nothing; the 4-week and 12-week trends tell the real story. WatchMyHealth's weight tracker shows your moving average and projected trajectory — exactly the data your physician wants to see at follow-up appointments.

  • Monitor your food intake, especially protein. Reduced appetite is the point of these drugs, but reduced appetite can lead to inadequate nutrition if you are not deliberate about what you eat. Logging meals helps ensure you hit protein targets even when you are not hungry.

  • Log your medication consistently. Tracking when you take your injection, what dose you are on, and any side effects creates a record that is invaluable for your clinical team — especially during dose titration or if you switch between medications.

  • Use your data to have better conversations with your doctor. The combination of weight trends, food logs, and medication records gives your healthcare provider objective information that goes far beyond "I think it's working" or "I feel like I'm not losing."

The science of GLP-1 drugs is still being written. New indications, new molecules, and new data will continue to emerge. What will not change is the fundamental principle: the best decisions are made with good data, and the best health outcomes come from combining effective treatments with sustainable habits.